Legion Peptides Retatrutide: A Research Buyer's Guide

Legion Peptides Retatrutide is a research-grade supply of an investigational triple agonist. Here's what US buyers should check before ordering.

ARTICLE OVERVIEW

Legion Peptides Retatrutide is a research-grade supply of an investigational triple agonist. Here's what US buyers should check before ordering.

Legion Peptides retatrutide is marketed as a research-use-only (RUO) chemical, not as an FDA-approved medicine. Retatrutide is an investigational triple agonist that has not been approved for human use in the United States, so any listing under that name is a laboratory product rather than a prescription treatment. Buyers should evaluate it the way they would any other research peptide: by documentation, not by marketing claims.

What Retatrutide Actually Is

Retatrutide (also written LY3437943) is an experimental peptide that activates three receptors at once: GLP-1, GIP, and glucagon. Eli Lilly has studied it in clinical trials for obesity and type 2 diabetes, and the results have been covered widely in US media.

Retatrutide is not FDA-approved for any indication, and it is not available by prescription in the United States. That regulatory status is the single most important fact for anyone researching the compound.

The "research use only" label on a vendor vial is a legal disclaimer, not a quality guarantee. It means the product is not intended for human or veterinary use and has not gone through the manufacturing, sterility, or dosing standards required of prescription drugs.

How Retatrutide Compares With Approved Incretin Drugs

Retatrutide is often discussed alongside semaglutide and tirzepatide, but the three are not interchangeable. The table below shows the main differences.

CompoundReceptor targetsFDA statusTypical route
SemaglutideGLP-1Approved (Ozempic, Wegovy)Weekly injection or oral
TirzepatideGIP + GLP-1Approved (Mounjaro, Zepbound)Weekly injection
RetatrutideGIP + GLP-1 + glucagonInvestigational onlyInjection (trial setting)

Because retatrutide is still investigational, no dosing schedule has been validated for general use. Trial protocols used weekly injections under medical supervision, with doses escalated slowly over months.

What a Legion Peptides Retatrutide Listing Should Include

When buyers compare peptides retatrutide options across suppliers, the paperwork matters more than the product photo. A credible RUO listing usually provides the following.

  • A third-party certificate of analysis (COA) from an independent lab, not just an in-house report.
  • HPLC purity data, typically 98% or higher, plus mass spectrometry confirmation of molecular weight.
  • A lot number that matches the vial you actually receive.
  • Lyophilized powder in a sealed, sterile-filtered vial with a desiccant.
  • Clear RUO labeling stating the product is not for human or veterinary use.

Most research peptides retatrutide products look nearly identical on a product page. The COA, the lot number, and the lab that issued the report are what separate a documented supplier from a reseller.

Vendor Comparison at a Glance

SourceThird-party testingFDA approvalStated intended use
Legion Peptides (RUO listing)Varies by lot; COAs often postedNoLaboratory research only
Other research peptide vendorsVaries widelyNoLaboratory research only
Compounding pharmaciesState and federal oversightNot available for retatrutidePrescription only
Brand-name prescription drugsManufacturer plus FDA reviewYes (semaglutide, tirzepatide)Human use under supervision

Reviews and forum posts can help narrow a shortlist, but they are not proof of quality. A written Ascension Peptides Retatrutide Review, for example, is only as useful as the testing data it cites. Listings such as core peptides retatrutide pages often publish a lot number and a downloadable COA, while others publish neither.

The same is true of true peptides retatrutide listings: they rise or fall on documentation quality. Price per milligram is a secondary signal, and unusually cheap vials are usually cheap for a reason.

What Retatrutide Costs and Why Prices Vary

Gray-market retatrutide is commonly advertised anywhere from roughly $50 to more than $200 per vial, depending on size, lot, and whether testing is included. Prices shift frequently, so any figure you see online should be treated as a snapshot.

  • Vial size: 5 mg, 10 mg, and larger vials lower the cost per milligram.
  • Testing: Vendors that pay for independent HPLC and mass spec charge more.
  • Kit contents: Bundles with bacteriostatic water and supplies cost more than a bare vial.
  • Shipping: Domestic US shipping is faster and usually more expensive than overseas shipping.

A low price per milligram is not a bargain if the vial cannot be traced to a lab report. In this market, documentation is the product.

Purity, Storage, and Handling

Lyophilized retatrutide is generally shipped at room temperature and stored refrigerated or frozen for long-term stability. Once reconstituted, most research peptides are kept cold and protected from light.

Purity claims above 99% are common in marketing but should always be backed by a chromatogram. A COA without a lot number, a lab name, or a test date is not useful documentation.

Retatrutide is not FDA-approved for human use in the United States. Selling peptides labeled for research is generally legal, but human use falls outside that labeling, and the FDA has issued repeated warnings about gray-market GLP-1 products.

Reported side effects in retatrutide trials included nausea, vomiting, diarrhea, constipation, and injection site reactions, with some participants stopping treatment because of gastrointestinal effects. Gallbladder and pancreatic events have also been reported with incretin-based drugs.

Research-grade vials carry risks that prescription drugs do not: no guaranteed sterility, no verified dose per vial, and no regulatory oversight of what is actually inside. Anyone considering a GLP-1 or triple agonist for weight or blood sugar should talk with a healthcare professional about approved options instead.

Bottom Line

Legion Peptides retatrutide is an RUO product from an unregulated market, and retatrutide remains an investigational drug with no approved human use. Buyers who still want to compare suppliers should judge them on third-party COAs, lot traceability, and transparent labeling rather than on price or reviews.

RELATED PEPTIDE TOPICRetatrutide peptide

Frequently Asked Questions

Is Legion Peptides retatrutide FDA-approved?

No. Retatrutide is an investigational triple agonist that has not been approved by the FDA for any indication. Legion Peptides and similar vendors sell it as a research-use-only chemical, which is not intended for human or veterinary use.

How is retatrutide different from tirzepatide and semaglutide?

Semaglutide targets only the GLP-1 receptor, while tirzepatide targets GIP and GLP-1. Retatrutide adds a third target, the glucagon receptor, which is why it is described as a triple agonist. Semaglutide and tirzepatide are FDA-approved; retatrutide is not.

What should I look for in a retatrutide certificate of analysis?

A useful COA lists the testing laboratory, the lot number matching your vial, the test date, an HPLC purity percentage, and mass spectrometry confirmation of molecular weight. Reports without a lab name or lot number cannot be tied to a specific batch and are of limited value.

Research information notice

This page provides educational research information and does not replace medical advice, diagnosis, or treatment.